Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Future developments in myeloma treatment

Sally Moore • 3 Apr 2022
BSH 2022
Multiple Myeloma Antibodies CAR-T

Sally Moore, MD, Royal United Hospital, Bath, UK, briefly discusses future developments in multiple myeloma (MM) treatment, drawing focus on the use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. Dr Moore also mentions the excitement surrounding other novel agents in myeloma treatment, their increasing efficacy, and the improved management of toxicities. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Sally Moore

1:20
Overview on the use of KRd for myeloma in a real-world setting
Sally Moore • 3 Apr 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals